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Glioblastoma multiforme (GBM) is the most malignant astrocytic tumour. Extra-neural 
spread is exceedingly rare, and usually develops at the time of intracranial progression following a 
surgical procedure (2-4). Less frequently, metastases are a consequence of spontaneous tumour 
trans-dural extension or haematogenous spread. Here, we describe two unusual cases of GBM in 
which scalp metastases appeared in the absence of intracranial disease progression. 
Case 1. A 48-year-old woman who presented with headache, speech disturbances and left 
facio-brachial paresis underwent magnetic resonance images (MRI), which revealed a large right 
fronto-parietal mass with a peripheral enhancement (Fig. 1a). The patient underwent gross total 
removal of the tumour, and a histopathological diagnosis of GBM was made. Using 
immunohistochemistry, the tumour cells were shown to co-express GFAP (intensely) and vimentin 
(less extensively). EGFR was positive in all tumour cells and YKL-40 showed a faint cytoplasm 
positivity in about 30% of cells (Fig 3). Conformal radiotherapy and adjuvant Temozolomide 
(TMZ) followed surgery. After 12 cycles, and in the absence of intracranial disease recurrence, the 
patient presented with a 2 cm scalp metastasis, close to but not contiguous with the surgical scar 
(Fig. 1b). A complete removal was performed and the diagnosis of GBM was confirmed. 
Histologically, the metastasis showed an infiltrating growth pattern dispersed into fibrotic tissue and 
consisted of a neoplastic population of large pleomorphic cells with a high mitotic index and strong 
positivity for vimentin, while the GFAP staining was less diffuse than in the intracranial tumour. 
Moreover, when compared with the primary lesion, EGFR was negative in the neoplastic cells, 
whereas a diffuse, intense YKL-40 immunoreactivity was found (Fig. 3). The patient underwent 
focal radiotherapy; four months later, an MRI revealed distant intracranial progression in the right 
temporal lobe. The patient received second-line chemotherapy but soon the progressive intracranial 
disease led to the patient’s death.  
Case 2. A 53-year-old woman presented with a one-month history of speech disturbances 
and facio-brachio-crural right motor deficit and underwent MRI, which showed a left frontal mass 
with contrast enhancement (Fig. 2a). She underwent craniotomy with partial resection of the mass, 
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and a diagnosis of GBM was made. Immunohistochemistry showed a diffuse and intense GFAP 
reactivity with vimentin co-expression in a few GFAP positive areas; EGFR positivity was diffuse, 
whereas YKL-40 showed weak and focal expression (Fig. 3). The patient underwent radiotherapy 
and standard TMZ treatment, and a partial response with a 90% reduction of the enhancing area was 
observed at MRI. Unexpectedly, the reduction of the intracranial disease was accompanied by the 
appearance of a mass in the scalp of the left parietal area, 2 cm away from the surgical scar (Fig. 
2b). A biopsy was performed and the histology was consistent with a recurrent GBM. The skin 
metastasis was mainly composed of small cells, all intensely vimentin positive, with only few 
neoplastic elements still immunoreactive to GFAP; EGFR was completely negative, whereas an 
intense YKL-40 staining was evident in the cytoplasm of the majority of neoplastic cells (Fig. 3). 
The patient received local radiotherapy and TMZ, but 3 months later three new cutaneous satellite 
lesions developed, despite the absence of any intracranial progression. Four months later, a new 
MRI demonstrated intracranial progression, and the patient died after 2 months.  
In both patients, the cutaneous metastases occurred close to the surgical scar, indicating the 
possibility of tumour spill during surgery and/or tumour trans-dural extension facilitated by the 
surgery. In contrast with the cases reported in literature, in which scalp metastases developed 
synchronously with intracranial progression, the metastases in the two cases reported here occurred 
in presence of a (radiologically) stable disease which may be attributed to radiotherapy and/or TMZ 
treatment. The acquisition of a divergent phenotype by the metastatic lesions could account for such 
differing responses to treatment. In fact, the immunophenotypical profile of the primary and 
cutaneous tumours showed two distinct patterns: in skin relapses, we observed dramatically reduced 
GFAP and EGFR staining paralleled by increased vimentin and YKL-40 expression. Although the 
“mesenchymal” markers vimentin and YKL-40 can be expressed in glioblastomas, the decrease of a 
very specific glial marker, such as GFAP, concomitant to the increase in vimentin/YKL40 
expression suggests at least a partial loss of the glial phenotype. In both cases, the primary tumours 
displayed only very few areas of neoplastic cells with the same immuno-profile of skin metastases. 
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This observation suggests the selection of an aggressive therapy-resistant sub-population of 
neoplastic cells in the metastatic sites, induced either by treatment (autopsy studies have previously 
reported on radiotherapy-induced morphological changes) (1) or determined by tumour 
environment, such as in transdifferentiation of glioma cells through a “mesenchymal drift” (5). 
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Legends 
 
Figure 1: Case 1: a: MRI demonstrating a large right fronto-parietal mass. b: MRI demonstrating 
the subcutaneous swelling without any visible recurrence of the intracranial disease (on T1-
weighted MR images after contrast) fourteen months after surgery.  
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Figure 2. Case 2: a: MRI demonstrating a left frontal mass. b: MRI demonstrating the scalp 
metastasis, nine months after surgery, without any intracranial progression.  
Figure 3: Histological and immunophenotypical patterns of the two cases studied. 
Case 1. The primary tumour was characterized by pseudo-palisading necrosis and vascular 
proliferation with endothelial hyperplasia with pleomorphic cells with oval-to-elongated nuclei (a). 
The GFAP reactivity was strongly and diffusely present (b) whereas the vimentin immunoreaction 
was less extensive (c). YKL-40 staining showed a focal, faint cytoplasmic positivity (d) and EGFR 
was diffusely positive in neoplastic cells (e). The metastatic tumour exhibited areas of necrosis and 
vascular proliferation with a population constituted by pleomorphic cells (f) mainly immunoreactive 
to vimentin (h). The GFAP stain was less diffuse than in the primary lesion (g) whereas the YKL-
40 immunoreactivity was increased (i) and EGFR was negative (j).  
Case 2. The primary tumour showed a marked hypercellularity with pseudo-palisading necrosis, 
glomeruloid vascular proliferation (k) and an intense GFAP reactivity and a minor vimentin 
expression (l, m). YKL-40 showed focal expression (n) and EGFR immunoreactivity was diffusely 
present (o). The metastatic tumour was extensively necrotic and mainly composed of neoplastic 
cells with a small and hyperchromic nuclei (p); only a few neoplastic elements were 
immunoreactive to GFAP (q), whereas the majority of tumour cells were intensely vimentin 
positive (r). YKL-40 staining was diffuse in the cytoplasm of tumour cells (s) whereas the EGFR 
immunoreaction was negative (t).  
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